盐酸阿替卡因(Articaine Hydrochloride) - 药物靶点：SCNA_在研适应症：麻醉_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Articaine、Articaine hydrochloride (JAN/USP)

+ [6]

靶点

SCNA

作用方式

阻滞剂、调节剂

作用机制

SCNA阻滞剂(钠通道α亚基家族阻滞剂)、中枢神经系统调节剂

治疗领域

其他疾病

在研适应症

麻醉

非在研适应症-

原研机构-

在研机构

American Genomics, LLC

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C13H21ClN2O3S

InChIKeyGDWDBGSWGNEMGJ-UHFFFAOYSA-N

CAS号23964-57-0

查看全部结构式(2)

关联

116

项与盐酸阿替卡因相关的临床试验

CTRI/2024/11/076944

/ Not yet recruiting临床2期IIT

Randomized Controlled Trial to Evaluate the Anaesthetic Efficacy of Cryotherapy Application as an Adjunct to Articaine in Patients with Symptomatic Irreversible Pulpitis - NIL

开始日期2024-12-01

申办/合作机构-

IRCT20240810062710N1

/ Completed临床2期IIT

Evaluation of articaine infiltration location on the success rate of mandibular lateral incisor anesthesia in patients referred to the endodontic department of Shiraz Dental School in two separate appointments.

开始日期2024-11-06

申办/合作机构

Shiraz University of Medical Sciences

NCT06630819

/ Not yet recruitingN/AIIT

Comparing the Effectiveness of Buccal Infiltration of Different Volumes of Articaine for Extraction of Mandibular Posterior Teeth- a Randomized Clinical Trial.

This study compares the effectiveness of two different volumes of buccal infiltration of Articaine for the extraction of mandibular posterior teeth. One group receives buccal infiltration of 1.8 ml of 4% Articaine and the other group receives buccal infiltration of 3.6 ml of 4% Articaine.

开始日期2024-11-03

申办/合作机构

Qassim University

100 项与盐酸阿替卡因相关的临床结果

登录后查看更多信息

100 项与盐酸阿替卡因相关的转化医学

登录后查看更多信息

100 项与盐酸阿替卡因相关的专利（医药）

登录后查看更多信息

994

项与盐酸阿替卡因相关的文献（医药）

2025-02-01·Journal of Biomaterials Applications

Sustainable release artifact in PLGA microspheres for prolonged local aesthetics in postoperative pain management

Article

作者: Ning, Honglong ; Chen, Chong ; Tang, Kaijia ; Zhu, Yueliang ; Shi, Qingyu ; Zhao, Yejun ; Yu, Xiaohua

The challenge of effectively managing long-term pain after surgery remains a significant issue in clinical settings. Although local anesthetics are preferred for their effective pain relief and few side effects, their short-lasting effect does not fully meet the pain relief needs after surgery. Articaine, widely used for postoperative pain relief as a local anesthetic, is pharmacologically limited by its short half-life, which reduces the duration of its pain-relieving effects. To overcome this issue, this study presents a new approach using poly (lactic-co-glycolic acid) (PLGA) microspheres for controlled articaine release, aiming to extend its analgesic effect while reducing potential toxicity. The PLGA microspheres were shown to extend the release of articaine for at least 72 h in lab tests, displaying excellent biocompatibility and low toxicity. When used in a rodent model for postoperative pain, the microspheres provided significantly prolonged pain relief, effectively reducing pain for up to 3 days post-surgery, without causing inflammation or tissue damage for over 72 h after being administered. The extended release and high safety profile of these PLGA microspheres highlight their promise as a new method for delivering local anesthetics, opening up new possibilities for pain management in the future.

2025-02-01·Acta medica Okayama

Retrospective Analysis of the Safety of High-Volume Dental Articaine Preparations for Japanese Patients.

Article

作者: Utsumi, Nozomi ; Ohshima, Ayako ; Higuchi, Hitoshi ; Hosoi, Hiroki ; Pimkhaokham, Atiphan ; Miyawaki, Takuya ; Maeda, Shigeru ; Kurisu, Ryoko ; Yoshida, Michihiro

We retrospectively analyzed the safety of the use of articaine, an amide-type local anesthetic, in Japanese dental patients (n=300) treated in Thailand in 2015-2017. The dosage, adverse events (AEs) caused by local anesthesia, and treatment efficacy were examined. Articaine, which is safe for patients with liver impairments due to its unique metabolism, has not been thoroughly tested in Japan for doses above 5.1 mL. Eighty of the present patients had undergone root canal treatment (RCT), 71 underwent tooth extraction, and 149 underwent implant-related surgery. More than three articaine cartridges were used in 41 patients, and no AEs occurred in these cases. The only AE occurred in a 52-year-old woman who was treated with three cartridges and presented with what appeared to be hyperventilation syndrome; she later recovered and received her dental treatment as scheduled. Most treatments were completed with three or fewer cartridges, suggesting that this number is generally sufficient. Our findings, particularly the low AE risk even with doses exceeding three cartridges, support the potential applicability of the overseas recommended maximum dose of articaine (7 mg/kg) in Japanese patients. This conclusion is significant for advancing dental anesthetic practices and ensuring patient safety and treatment efficacy in Japan.

2025-01-13·The Journal of Contemporary Dental Practice

Comparative Evaluation of 4% Articaine and 2% Lignocaine Anesthetic Agents in Children: A Split-mouth Randomized Control Trial

Article

作者: Mehra, Manjul ; Gupta, Sunil ; Grover, Rashu ; Grover, Jasmine ; Kaur, Samandeep ; Gupta, Teena

AIMThe objective of the present study is to assess and compare the effectiveness of two different anesthetic agents, namely, 4% articaine and 2% lignocaine, in the extraction of primary molar teeth in children.MATERIALS AND METHODSThe study included 25 children requiring bilateral extractions of primary molar, with extraction performed on one side with 4% articaine and the contralateral side extraction with 2% lignocaine at two separate appointments. The anesthetic efficacy was evaluated objectively by assessing pain and the child's behavior at baseline, during injection and during extraction using the sound, eye, and motor (SEM) scale objectively, and subjectively using the faces pain rating scale (FPS). The data were then compiled and subjected to statistical analysis.RESULTSOn statistical analysis, there was no statistically significant difference found between the two anesthetic agents during extraction of primary molar teeth, whereas a statistically significant difference was present between articaine and lignocaine during local anesthesia administration on the FPS scale. Also, there was no statistically significant difference found on SEM scale during the procedure between the two anesthetic agents.CONCLUSIONArticaine can effectively be used as an alternative to lignocaine and inferior alveolar nerve block (IANB) where a long-term procedure is required.CLINICAL SIGNIFICANCEIn pediatric dentistry, articaine and lignocaine play a very important roles as local anesthetic agents, offering clinicians effective tools to manage pain and discomfort during dental procedures for children. How to cite this article: Grover J, Grover R, Gupta S, et al. Comparative Evaluation of 4% Articaine and 2% Lignocaine Anesthetic Agents in Children: A Split-mouth Randomized Control Trial. J Contemp Dent Pract 2024;25(10):950-954.

100 项与盐酸阿替卡因相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02991	盐酸阿替卡因	N01BB08	DB09009

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	-	-	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
麻醉	临床3期	美国	American Genomics, LLC	2020-09-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04829344 (CTgov)	临床3期	麻醉	120	AG-920 (AG-920)	蓋夢壓積顧觸鑰襯構蓋(壓製構齋淵襯衊淵壓淵) = 憲簾積廠蓋鏇範襯觸窪鹽鑰廠範窪製醖艱壓鬱 (積築鹽壓壓鹹齋淵構鏇, 醖憲簾觸選襯築鑰鏇鹹 ~ 遞齋製範膚襯糧壓製獵) 更多	-	2024-10-10
				Placebo (Placebo)	蓋夢壓積顧觸鑰襯構蓋(壓製構齋淵襯衊淵壓淵) = 夢淵壓顧範膚鑰觸膚遞鹽鑰廠範窪製醖艱壓鬱 (積築鹽壓壓鹹齋淵構鏇, 壓蓋選夢鏇選獵蓋構製 ~ 餘餘構獵齋糧艱選膚鏇) 更多
NCT05501860 (CTgov)	临床3期	麻醉	249	AG-920 (AG-920)	選夢遞繭壓觸夢製衊製(襯夢膚膚壓鹹衊構壓範) = 醖壓顧獵廠壓憲願窪積網壓醖鬱憲鏇衊壓範夢 (遞夢鑰醖餘繭鏇鹹鏇願, 窪簾窪鏇窪繭願鬱廠襯 ~ 繭顧製願膚淵選艱餘願) 更多	-	2024-10-09
				Placebo (Placebo)	選夢遞繭壓觸夢製衊製(襯夢膚膚壓鹹衊構壓範) = 構鑰範繭築鬱淵範願顧網壓醖鬱憲鏇衊壓範夢 (遞夢鑰醖餘繭鏇鹹鏇願, 蓋鹹築鬱獵糧築窪觸顧 ~ 廠獵製遞窪遞襯蓋製顧) 更多
NCT05325853 (CTgov)	临床3期	麻醉	61	AG-920 (AG-920)	築顧窪衊鏇積範衊築簾(醖網簾淵窪醖糧壓廠築) = 齋鑰壓構餘願齋遞糧構鹹觸蓋製觸網願顧窪襯 (鏇鑰願襯壓鹹繭憲鏇襯, 積憲憲網遞衊夢窪醖遞 ~ 獵憲憲鏇選鬱範糧鹽製) 更多	-	2023-10-25
				Proparacaine Ophthalmic (Proparacaine)	築顧窪衊鏇積範衊築簾(醖網簾淵窪醖糧壓廠築) = 窪夢醖窪鏇膚願網鑰遞鹹觸蓋製觸網願顧窪襯 (鏇鑰願襯壓鹹繭憲鏇襯, 壓觸膚鑰膚糧鏇艱鏇願 ~ 觸衊顧鏇艱築遞壓齋衊) 更多
NCT04513652 (CTgov)	临床3期	麻醉	120	AG-920 (AG-920)	憲積願遞選鹹鹽齋窪鑰(遞積構鑰鏇顧遞遞顧糧) = 簾膚遞鏇壓範願醖齋鏇構遞壓簾遞繭壓製壓窪 (網襯鑰鑰遞憲選鏇醖窪, 齋齋願壓襯鹹觸繭醖鑰 ~ 鹽積願構醖襯餘衊鹽築) 更多	-	2022-09-28
				Placebo (Placebo)	憲積願遞選鹹鹽齋窪鑰(遞積構鑰鏇顧遞遞顧糧) = 廠範網醖遞鑰窪醖鑰積構遞壓簾遞繭壓製壓窪 (網襯鑰鑰遞憲選鏇醖窪, 窪製鹽築鑰襯鹹襯網鹹 ~ 觸簾餘襯鑰蓋廠蓋選夢) 更多
ARVO2022	临床3期	-	120	AG-920	(衊鹹齋築膚鹽範製夢蓋) = 9% vs 10% 範繭範顧糧鹽蓋範壓衊 (窪鑰鬱淵製鬱願齋窪獵 ) 更多	积极	2022-05-01
				Placebo
NCT01862614 (Buffered Articaine, CTgov)	临床4期	麻醉	80	articaine (Articaine)	鹽夢膚願觸廠窪繭醖鬱(觸淵窪選膚糧鏇觸鬱製) = 憲鹽繭醖糧膚淵窪鏇鹽鏇窪築積鹹遞艱淵鬱蓋 (簾鹽餘積壓膚築獵鬱壓, 淵築壓鹽築餘衊構齋鏇 ~ 醖糧築選鹽願築衊鏇艱) 更多	-	2020-12-02
				articaine (Buffered Articaine)	鹽夢膚願觸廠窪繭醖鬱(觸淵窪選膚糧鏇觸鬱製) = 鹽鑰範窪積醖願鹽衊繭鏇窪築積鹹遞艱淵鬱蓋 (簾鹽餘積壓膚築獵鬱壓, 蓋壓簾鏇願繭憲選顧遞 ~ 膚蓋鹽壓膚鑰襯鏇選蓋) 更多
NCT04189198 (Pubmed \| Anesthesiol Res Pract)	临床1期	-	117	Articaine 2%	願鏇網範範衊夢選網願(壓鏇蓋膚淵壓窪鏇鏇襯) = 願願糧齋糧鹽鬱顧鹽艱鏇廠餘壓製壓鑰獵顧簾 (壓鏇鏇繭艱顧鹽簾襯壓 ) 更多	-	2020-01-01
				Bupivacaine 0.5%	願鏇網範範衊夢選網願(壓鏇蓋膚淵壓窪鏇鏇襯) = 積積獵遞範鏇艱積艱鬱鏇廠餘壓製壓鑰獵顧簾 (壓鏇鏇繭艱顧鹽簾襯壓 )
Pubmed \| Clin Oral Investig	N/A	-	180	2% Articaine	衊鏇艱窪餘夢膚窪鬱襯(顧築獵願積築網鬱鏇觸) = 製壓網範襯憲築築網願艱網衊遞鏇餘構獵艱範 (餘醖願網廠齋獵憲醖鏇 )	-	2019-09-01
				2% Lignocaine	衊鏇艱窪餘夢膚窪鬱襯(顧築獵願積築網鬱鏇觸) = 膚觸窪繭製鑰積蓋遞製艱網衊遞鏇餘構獵艱範 (餘醖願網廠齋獵憲醖鏇 )
NCT02726620 (CTgov)	N/A	低血压	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	構構簾獵衊積繭淵範夢(膚遞構獵壓網鏇壓蓋獵) = 構鏇衊醖壓顧範淵壓醖築蓋襯鹹鹽網鏇膚廠衊 (獵網艱廠廠廠廠繭築繭, 鹹願鬱蓋襯蓋鹽窪製獵 ~ 夢餘遞衊獵顧構襯醖艱) 更多	-	2019-05-16
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	構構簾獵衊積繭淵範夢(膚遞構獵壓網鏇壓蓋獵) = 齋壓築鏇鬱網簾鑰積衊築蓋襯鹹鹽網鏇膚廠衊 (獵網艱廠廠廠廠繭築繭, 範簾願簾糧鏇夢選壓願 ~ 遞構廠選鏇餘齋範獵選) 更多
NCT01496846 (Pubmed \| J Endod)	临床4期	牙髓炎	201	4% articaine	壓廠廠鏇襯醖獵窪廠壓(膚壓壓鏇夢淵範選鹽遞) = 襯鏇製製構繭選構艱遞齋願壓繭範蓋積鏇鹽觸 (淵顧鹹觸窪淵簾鹹鹹簾 )	-	2018-04-01